|本期目录/Table of Contents|

[1]吴权,张建平,程荣,等.莫西沙星孟鲁司特钠对社区获得性肺炎疗效及炎症因子的影响[J].中华肺部疾病杂志,2022,(06):882-884.[doi:10.3877/cma.j.issn.1674-6902.2022.06.032]
点击复制

莫西沙星孟鲁司特钠对社区获得性肺炎疗效及炎症因子的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年06期
页码:
882-884
栏目:
短篇论著
出版日期:
2022-12-20

文章信息/Info

Title:
-
作者:
吴权; 张建平; 程荣; 陈礼龙
201505 上海,上海市金山区亭林医院急诊科
Author(s):
-
关键词:
社区获得性肺炎;  莫西沙星;  孟鲁司特钠;  炎症因子
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.06.032
摘要:
-
Abstract:
-

参考文献/References:

1 刘 熙, 李 琦. 我国成人社区获得性肺炎诊疗现状及思考[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(3): 387-389.
2 Torres A, Cilloniz C, Niederman MS, et al. Pneumonia[J]. Nat Rev Dis Primers, 2021, 7(1): 25.
3 Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia[J]. Med Clin North Am, 2019, 103(3): 487-501.
4 Ho J, Ip M. Antibiotic-resistant community-acquired bacterial pneumonia[J]. Infect Dis Clin North Am, 2019, 33(4): 1087-1103.
5 王晓航. 左氧氟沙星与莫西沙星对老年社区获得性肺炎患者临床治疗的有效性比较[J]. 抗感染药学, 2020, 17(1): 119-122.
6 李会涛. 左氧氟沙星与莫西沙星对老年社区获得性肺炎患者治疗的有效性比较[J]. 航空航天医学杂志, 2021, 32(7): 788-790.
7 Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019(COVID-19)pandemic[J]. Ann Intern Med, 2020, 173(4): 304-305.
8 白 冰. 莫西沙星与左氧氟沙星序贯治疗老年社区获得性肺炎对患者肺功能的影响与安全性比较[J]. 临床合理用药杂志, 2021, 14(11): 83-84.
9 孙银春. 莫西沙星与左氧氟沙星序贯治疗老年社区获得性肺炎的临床疗效及安全性比较[J]. 临床合理用药杂志, 2019, 12(4): 18-19.
10 Olson G, Davis AM. Diagnosis and treatment of adults with community-acquired pneumonia[J]. JAMA, 2020, 323(9): 885-886.
11 徐 意, 朱 峰, 黄振荣, 等. 莫西沙星对老年社区获得性肺炎患者抗感染疗效及肺功能的影响[J]. 中华医院感染学杂志, 2018, 28(4): 485-487+507.
12 陈晓红, 陈秀红, 陈向红. 莫西沙星对老年CAP患者肺功能及血清CRP、PCT、sTREM-1水平的影响[J]. 贵州医科大学学报, 2020, 45(4): 477-481.
13 窦阳旭, 张鹏飞.孟鲁司特钠咀联合莫西沙星对肺炎患者临床效果及血清LHP、SOD、MDA的影响[J].航空航天医学杂志, 2021, 32(5):583-584.
14 方 江, 艾红艳, 秦永刚, 等. 莫西沙星对老年社区获得性肺炎患者血清炎症因子及免疫功能的影响[J]. 中外医学研究, 2020, 18(1): 3-5.
15 曾 鹏, 曹 骏, 廖梅蓉. 氨溴索辅助莫西沙星对老年社区获得性肺炎患者的临床疗效及其对炎症因子水平的影响[J]. 抗感染药学, 2020, 17(8): 1232-1235.
16 肖 洁, 简丽萍, 雷苟发. 莫西沙星序贯治疗老年社区获得性肺炎(CAP)的效果及对肺功能和炎症因子水平的影响[J]. 北方药学, 2019, 16(12): 85-86.
17 Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults[J]. BMJ, 2017, 358: 2471.
18 Froes F, Pereira JG, Póvoa P. Outpatient management of community-acquired pneumonia[J]. Curr Opin Infect Dis, 2018, 31(2): 170-176.
19 Prina E, Ranzani OT, Torres A. Community-acquired pneumonia[J]. Lancet, 2015, 386(9998): 1097-1108.
20 Rothberg MB. Community-acquired pneumonia[J]. Ann Intern Med, 2022, 175(4): ITC49-ITC64.
21 Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU[J]. Pharmacol Ther, 2021, 217: 107663.
22 Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia[J]. Med Clin North Am, 2019, 103(3): 487-501.
23 Smith DK, Kuckel DP, Recidoro AM. Community-acquired pneumonia in children: Rapid evidence review[J]. Am Fam Physician, 2021, 104(6): 618-625.
24 Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update[J]. Indian J Med Res, 2020, 151(4): 287-302.
25 le Roux DM, Zar HJ. Community-acquired pneumonia in children-a changing spectrum of disease[J]. Pediatr Radiol, 2017, 47(11): 1392-1398.
26 Torres A, Chalmers JD, Dela Cruz CS, et al. Challenges in severe community-acquired pneumonia: a point-of-view review[J]. Intensive Care Med, 2019, 45(2): 159-171.
27 Franquet T. Imaging of community-acquired pneumonia[J]. J Thorac Imaging, 2018, 33(5): 282-294.
28 Losier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia[J]. Curr Opin Infect Dis, 2022, 35(2): 128-132.
29 Wunderink RG. Guidelines to manage community-acquired pneumonia [J]. Clin Chest Med, 2018, 39(4): 723-731.
30 Liapikou A, Cilloniz C, Palomeque A, et al. Emerging antibiotics for community-acquired pneumonia[J]. Expert Opin Emerg Drugs, 2019, 24(4): 221-231.

备注/Memo

备注/Memo:
通信作者: 陈礼龙, Email: chenlilong19842022@163.com
更新日期/Last Update: 2022-12-20